US 12,030,952 B2
Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
Harald Duerr, Starnberg (DE); Sebastian Fenn, Achmuehle/Eurasburg (DE); Ulrich Goepfert, Penzberg (DE); Sabine Imhof-Jung, Krailling (DE); Christian Klein, Bonstetten (CH); Laurent Lariviere, Westendorf (DE); Michael Molhoj, Munich (DE); Joerg Thomas Regula, Munich (DE); Petra Rueger, Penzberg (DE); and Wolfgang Schaefer, Mannheim (DE)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on May 23, 2022, as Appl. No. 17/664,609.
Application 17/664,609 is a continuation of application No. 16/822,972, filed on Mar. 18, 2020, abandoned.
Application 16/822,972 is a continuation of application No. 15/941,524, filed on Mar. 30, 2018, granted, now 11,603,411.
Application 15/941,524 is a continuation of application No. PCT/EP2016/073413, filed on Sep. 30, 2016.
Claims priority of application No. 15188067 (EP), filed on Oct. 2, 2015.
Prior Publication US 2022/0306761 A1, Sep. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 25/00 (2006.01)
CPC C07K 16/2887 (2013.01) [A61P 25/00 (2018.01); C07K 16/2881 (2013.01); C07K 2317/31 (2013.01); C07K 2317/515 (2013.01); C07K 2317/522 (2013.01); C07K 2317/55 (2013.01); C07K 2317/66 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 10 Claims
 
1. A bispecific antibody binding to human CD20 and human transferrin receptor comprising:
a first light chain comprising the amino acid sequence of SEQ ID NO: 01,
a first heavy chain comprising the amino acid sequence of SEQ ID NO: 02,
a second light chain comprising the amino acid sequence of SEQ ID NO: 03, and
a second heavy chain comprising the amino acid sequence of SEQ ID NO: 10.